Noxopharm CEO Dr Gisela Mautner announces resignation

Sydney-based clinical-stage biotech Noxopharm (ASX:NOX) has announced the resignation of its CEO and Managing Director, Dr Gisela Mautner, effective April 14.

Dr Mautner first joined the company in 2019 as chief medical officer before elevating to the top executive role in early 2022.

During her four-year tenure, she was credited by Chairman Fred Bart for overseeing a significant shift in the company’s strategic direction.

Noxopharm, which specialises in mRNA safety and treatments for cancer and inflammation through its Sofra and Chroma platforms, confirmed that a successor is expected to be named in the near future.

At the time of reporting, Noxopharm’s share price was $0.058.